Brokerages Set Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Price Target at $17.33

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) has been given a consensus rating of “Buy” by the six ratings firms that are presently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average twelve-month price target among brokers that have covered the stock in the last year is $17.33.

A number of brokerages have recently commented on TNYA. Piper Sandler reiterated an “overweight” rating on shares of Tenaya Therapeutics in a report on Friday, October 18th. Chardan Capital reiterated a “buy” rating and set a $18.00 price target on shares of Tenaya Therapeutics in a report on Wednesday, December 18th. Canaccord Genuity Group restated a “buy” rating and issued a $16.00 target price on shares of Tenaya Therapeutics in a research note on Friday, October 18th. Leerink Partners reaffirmed an “outperform” rating on shares of Tenaya Therapeutics in a research report on Friday, October 18th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $18.00 target price on shares of Tenaya Therapeutics in a research report on Monday, February 3rd.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. The Manufacturers Life Insurance Company lifted its position in Tenaya Therapeutics by 43.2% in the second quarter. The Manufacturers Life Insurance Company now owns 23,199 shares of the company’s stock worth $72,000 after purchasing an additional 7,000 shares during the period. State Street Corp raised its stake in Tenaya Therapeutics by 0.9% during the third quarter. State Street Corp now owns 1,058,898 shares of the company’s stock worth $2,044,000 after acquiring an additional 9,506 shares in the last quarter. Synovus Financial Corp acquired a new position in Tenaya Therapeutics during the third quarter worth $28,000. SG Americas Securities LLC raised its stake in Tenaya Therapeutics by 61.9% during the fourth quarter. SG Americas Securities LLC now owns 41,270 shares of the company’s stock worth $59,000 after acquiring an additional 15,777 shares in the last quarter. Finally, XTX Topco Ltd raised its stake in Tenaya Therapeutics by 51.2% during the third quarter. XTX Topco Ltd now owns 49,290 shares of the company’s stock worth $95,000 after acquiring an additional 16,687 shares in the last quarter. 90.54% of the stock is owned by institutional investors.

Tenaya Therapeutics Stock Up 5.5 %

Shares of TNYA stock opened at $0.95 on Friday. Tenaya Therapeutics has a 12 month low of $0.86 and a 12 month high of $7.01. The firm has a market cap of $75.03 million, a PE ratio of -0.66 and a beta of 2.84. The stock has a 50 day moving average of $1.58 and a 200-day moving average of $2.13.

Tenaya Therapeutics Company Profile

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.